CACNA1D and prostate cancer: Stratification of patient data, e.g., in prostate cancer by the presence of the TMPRS2-ERG fusion status (Tomlins et al. 2008) where it is known that CACNA1D is highly overexpressed, may show benefits of CCB use prior to development of aggressive disease.